Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dose Fractionation Clear all
Completed Phase 2 Interventional Results available

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

NCT00809991
View directory record Official record
Conditions
Prostate Cancer
Interventions
hypofractionation
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

NCT04454528
View directory record Official record
Conditions
Breast Cancer
Interventions
Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling
Radiation · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

NCT00557492
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
Drug · Radiation
Lead sponsor
Amer Zureikat
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 11, 2026, 5:13 PM EDT
Terminated Not applicable Interventional Results available

Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

NCT02672033
View directory record Official record
Conditions
Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 11, 2026, 5:13 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

NCT03972930
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Hypofractionated Radiotherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Recruiting Phase 3 Interventional

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

NCT07566156
View directory record Official record
Conditions
Urothelial Cancer, Urinary Bladder Neoplasms
Interventions
Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab
Drug · Radiation
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
13
States / cities
Santa Barbara, California • Aurora, Colorado • Newark, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT04172532
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Duarte, California • Irvine, California • Orange, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Recruiting Phase 2 Interventional

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

NCT06078709
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab
Procedure · Drug · Radiation + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

NCT01682226
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Lymphoma
Interventions
CliniMACS Fractionation system (Arm A), CliniMACS Fractionation system (Arm B), Haploidentical donor CD34+ cells
Device · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

NCT03715946
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
Interventions
Nivolumab Injection, Radiotherapy (RT)
Drug · Radiation
Lead sponsor
Robert L. Ferris, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Portland, Oregon • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 11, 2026, 5:13 PM EDT
Active, not recruiting Phase 3 Interventional

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

NCT03987386
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Houston, Texas • League City, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Not yet recruiting Phase 2 Interventional

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

NCT06712433
View directory record Official record
Conditions
Sarcoma,Soft Tissue
Interventions
2% intranasal mupirocin ointment, 4% chlorhexidine gluconate body cleanser
Drug
Lead sponsor
Adam Olson
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

NCT03040999
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
24
States / cities
Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

NCT01985087
View directory record Official record
Conditions
Glioblastoma
Interventions
Hypofractionated radiotherapy, Temozolomide
Radiation · Drug
Lead sponsor
University of Louisville
Other
Eligibility
70 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma

NCT01580969
View directory record Official record
Conditions
Recurrent Glioma
Interventions
Bevacizumab, Minocycline, Radiation
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer

NCT00581256
View directory record Official record
Conditions
Breast Cancer
Interventions
IMRT, 3D
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 11, 2026, 5:13 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

NCT05691829
View directory record Official record
Conditions
NSCLC Stage IV
Interventions
Pembrolizumab, Radiation, Chemotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 11, 2026, 5:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer

NCT04403620
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Intensity-modulated Radiation Therapy (IMRT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Terminated Phase 3 Interventional

Treatment of Childhood Acute Lymphoblastic Leukemia

NCT00165087
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
asparaginase (E. Coli), asparaginase (Erwina), dexrazoxane, doxorubicin, cranial radiation (once daily fractionation), cranial radiation (twice-daily fractionation), Intrathecal chemotherapy without radiation
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 18 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
6
States / cities
New Orleans, Louisiana • Lewiston, Maine • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Not applicable Interventional Results available

Mathematical Model-Adapted Radiation In Glioblastoma

NCT03557372
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Mathematical Model-Adapted Radiation Fractionation Schedule
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 11, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

NCT03043807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 11, 2026, 5:13 PM EDT
Terminated Phase 3 Interventional

S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx

NCT00268372
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, docetaxel, 5-fluorouracil, surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
74
States / cities
Norwich, Connecticut • Aurora, Illinois • Chicago, Illinois + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 11, 2026, 5:13 PM EDT
Suspended Phase 1Phase 2 Interventional

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

NCT04683653
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Hypofractionated Radiation, Clinical Follow-Up and Assessments
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 11, 2026, 5:13 PM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 11, 2026, 5:13 PM EDT